A courageous six-year-old girl has regained her vision through a remarkable life-altering eye gene therapy provided by the NHS.
Saffie Sandford, a young resident of Stevenage in Hertfordshire, was diagnosed with Leber’s Congenital Amaurosis (LCA), a rare inherited condition that inhibits the eye cells from producing necessary proteins for normal vision.
Individuals with this condition, particularly babies and children, experience limited vision in daylight and complete blindness in low light conditions, eventually facing potential total blindness in adulthood.
Saffie, a vibrant child who adores Spider-Man, was diagnosed with LCA at the age of five when her parents observed her struggle with vision in dim lighting.
After undergoing tests at Moorfields Eye Hospital in London, Saffie received the groundbreaking eye gene therapy, Luxturna, at Great Ormond Street Hospital. This pioneering treatment involves injecting a healthy gene copy directly into the eye, targeting one of the genetic triggers of LCA.
Saffie’s mother, Lisa, expressed her astonishment at the diagnosis and gratitude for the available NHS treatment that prevented Saffie from facing blindness by the age of 30. She described the treatment as transformative, allowing Saffie to see in the dark and enhancing her peripheral vision during the day.
The efficacy of Luxturna was highlighted in recent research by Gosh and University College London (UCL), indicating improved visual pathways in children with RPE65-related retinal disease. The study involved treating children as young as 15 months up to 12 years, demonstrating enhanced visual function in younger participants due to treatment timing during critical visual development stages.
While Luxturna is not deemed a definitive cure, researchers remain hopeful about its long-term benefits and plan to collect extensive data on its outcomes. Consultant ophthalmologist Rob Henderson emphasized the significance of gene therapy in strengthening visual pathways for children with inherited retinal diseases, underscoring the positive impact on their quality of life.
The utilization of pattern visual evoked potentials (VEPs) in assessing treatment outcomes in children was lauded as a potential standard for future gene therapy trials. This advancement not only showcases the potential of gene therapy in reshaping possibilities for children with genetic eye conditions but also stresses the importance of age-appropriate outcome evaluations in pediatric research.
